Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKelly C. Goldsmith, Yaël P. Mossé, Yueh‐Yun Chi et al.|Nature Medicine|2023Cited by 125
Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic MarkersAndré Oberthuer, Matthias Fischer, Dilafruz Juraeva et al.|Clinical Cancer Research|2014Cited by 99